{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:45:21Z","timestamp":1790736321293,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxicology in Vitro"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.tiv.2011.05.002","type":"journal-article","created":{"date-parts":[[2011,5,10]],"date-time":"2011-05-10T06:13:10Z","timestamp":1305007990000},"page":"1480-1484","source":"Crossref","is-referenced-by-count":10,"title":["Evaluation of the genotoxicity and cytotoxicity of fexofenadine in cultured human peripheral blood lymphocytes"],"prefix":"10.1016","volume":"25","author":[{"given":"Ceren B\u00f6r\u00e7ek","family":"Kasurka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z\u00fclal Atl\u0131","family":"\u015eekero\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vedat","family":"\u015eekero\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.tiv.2011.05.002_b0005","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/102490791001700114","article-title":"Prolonged QT interval after fexofenadine overdose in the presence of hypokalemia and hypocalcaemia","volume":"17","author":"Aksakal","year":"2010","journal-title":"Hong Kong Journal of Emergency Medicine"},{"issue":"3","key":"10.1016\/j.tiv.2011.05.002_b0010","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/0272-4332.203031","article-title":"The tumorigenicity of mutagenic contact sensitizing chemicals","volume":"20","author":"Albert","year":"2000","journal-title":"Risk Analysis"},{"key":"10.1016\/j.tiv.2011.05.002_b0015","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1383-5742(00)00049-1","article-title":"IPCS guidelines for the monitoring of genotoxic effects of carcinogens in humans","volume":"463","author":"Albertini","year":"2000","journal-title":"Mutation Research"},{"key":"10.1016\/j.tiv.2011.05.002_b0020","first-page":"207","article-title":"Fexofenadine hydrochloride-a new anti-histaminic drug","volume":"3","author":"Amichai","year":"2001","journal-title":"Israel Medical Association Journal"},{"key":"10.1016\/j.tiv.2011.05.002_b0025","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0165-1218(88)90037-7","article-title":"Chromosome aberrations, mitogen-induced blastogenesis and proliferative rate index in peripheral lymphocytes from 106 control individuals of UK population","volume":"204","author":"Anderson","year":"1988","journal-title":"Mutation Research"},{"issue":"3","key":"10.1016\/j.tiv.2011.05.002_b0030","first-page":"170","article-title":"The effects of long-term fexofenadine use on the corrected QT (QTc) interval","volume":"37","author":"Ba\u015fkan","year":"2003","journal-title":"Turkderm"},{"key":"10.1016\/j.tiv.2011.05.002_b0035","first-page":"5589","article-title":"Carcinogenicity studies of astemizole in mice and rats","volume":"55","author":"Benze","year":"1995","journal-title":"Cancer Research"},{"issue":"3","key":"10.1016\/j.tiv.2011.05.002_b0040","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/carcin\/bgl177","article-title":"An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans","volume":"28","author":"Bonassi","year":"2007","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.tiv.2011.05.002_b0045","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.mrrev.2008.09.002","article-title":"Update on genotoxicity and carcinogenicity testing of 472 marketed pharmaceuticals","volume":"681","author":"Brambilla","year":"2009","journal-title":"Mutation Research"},{"key":"10.1016\/j.tiv.2011.05.002_b0050","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0165-1218(88)90036-5","article-title":"Consideration for population monitoring using cytogenetic techniques","volume":"204","author":"Carrano","year":"1988","journal-title":"Mutation Research"},{"key":"10.1016\/j.tiv.2011.05.002_b0055","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF00278875","article-title":"Occurrence of 1st division metaphases in human lymphocyte cultures","volume":"41","author":"Crossen","year":"1978","journal-title":"Human Genetics"},{"key":"10.1016\/j.tiv.2011.05.002_b0060","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1146\/annurev.pharmtox.38.1.63","article-title":"Predictive value of in vitro model systems in toxicology","volume":"38","author":"Davila","year":"1998","journal-title":"Annual Review of Pharmacology and Toxicology"},{"issue":"2","key":"10.1016\/j.tiv.2011.05.002_b0065","first-page":"59","article-title":"Allergic rhinoconjunctivitis in athletes-mechanisms of impaired performance and implications for management","volume":"23","author":"Derman","year":"2010","journal-title":"Current Allergy and Clinical Immunology"},{"key":"10.1016\/j.tiv.2011.05.002_b0070","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/em.2850130104","article-title":"Identification of aneuploidy-inducing agents using cytokinesis-blocked human lymphocytes and an anti-kinetochore antibody","volume":"13","author":"Eastmond","year":"1989","journal-title":"Environmental and Molecular Mutagenesis"},{"issue":"5","key":"10.1016\/j.tiv.2011.05.002_b0075","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1081-1206(10)62855-4","article-title":"H1-receptor antagonists: safety issues. Annals of Allergy","volume":"83","author":"Estelle","year":"1999","journal-title":"Asthma and Immunology"},{"key":"10.1016\/j.tiv.2011.05.002_b0080","series-title":"Handbook of Mutagenicity Test Procedures","first-page":"405","article-title":"Human peripheral blood lymphocytes for the analysis of chromosome aberrations in mutagen tests","author":"Evans","year":"1984"},{"key":"10.1016\/j.tiv.2011.05.002_b0085","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0027-5107(00)00065-8","article-title":"The in vitro micronucleus technique","volume":"455","author":"Fenech","year":"2000","journal-title":"Mutation Research"},{"key":"10.1016\/j.tiv.2011.05.002_b0090","first-page":"1179","article-title":"Preclinical safety studies with terfenadine","volume":"32","author":"Gibson","year":"1982","journal-title":"Arzneimittel-Forschung\/Drug Research"},{"issue":"1","key":"10.1016\/j.tiv.2011.05.002_b0095","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0733-8635(05)70229-1","article-title":"Antihistamines","volume":"19","author":"Greaves","year":"2001","journal-title":"Dermatologic Clinics"},{"key":"10.1016\/j.tiv.2011.05.002_b0100","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1517\/13543784.7.7.1045","article-title":"Therapeutic advantages of third generation antihistamines","volume":"7","author":"Handley","year":"1998","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/j.tiv.2011.05.002_b0105","first-page":"1203","article-title":"The effect of cyproheptadine on the chromosomes of human lymphocytes in vitro","volume":"27","author":"Hite","year":"1977","journal-title":"Arzneimittel-Forschung\/Drug Research"},{"key":"10.1016\/j.tiv.2011.05.002_b0110","first-page":"1","article-title":"ISCN, Report of the standing committee on human cytogenetic nomenclature","volume":"21","year":"1985","journal-title":"Birth Defects-Original Article Series"},{"key":"10.1016\/j.tiv.2011.05.002_b0115","first-page":"663","article-title":"Mutagenicity and clastogenicity studies with mizolastine","volume":"26","author":"Iwase","year":"1998","journal-title":"Yakuri Chiryo"},{"issue":"1","key":"10.1016\/j.tiv.2011.05.002_b0120","first-page":"23","article-title":"Relation of the occurrence of chromosome aberrations in human peripheral lymphocytes to the cell cycle","volume":"129","author":"Kalina","year":"1990","journal-title":"Casopis Lekaru Ceskych"},{"issue":"3","key":"10.1016\/j.tiv.2011.05.002_b0125","first-page":"1337","article-title":"Nonsedating antihistamines: pharmacology, clinical efficacy and adverse effects","volume":"45","author":"Kaliner","year":"1992","journal-title":"American Family Physician"},{"key":"10.1016\/j.tiv.2011.05.002_b0130","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.mrgentox.2003.07.005","article-title":"Report from the in vitro micronucleus assay working group","volume":"540","author":"Kirsch-Volders","year":"2003","journal-title":"Mutation Research"},{"key":"10.1016\/j.tiv.2011.05.002_b0135","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/em.20309","article-title":"\u0130n vitro evaluation of the genotoxicity of acetamiprid in human peripheral blood lymphocytes","volume":"48","author":"Kocaman","year":"2007","journal-title":"Environmental and Molecular Mutagenesis"},{"issue":"6","key":"10.1016\/j.tiv.2011.05.002_b0140","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1177\/019459989210700604.2","article-title":"Antihistamines and decongestants","volume":"107","author":"Krause","year":"1992","journal-title":"Otolaryngology\u2013Head and Neck Surgery"},{"key":"10.1016\/j.tiv.2011.05.002_b0145","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0887-2333(02)00123-6","article-title":"Cytogenetic evaluation of two nitroimidazole derivatives","volume":"17","author":"Lo\u00b4pez Nigro","year":"2003","journal-title":"Toxicology in vitro"},{"key":"10.1016\/j.tiv.2011.05.002_b0150","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0027-5107(78)90141-0","article-title":"Scanning-electron microscopy of chromosome aberrations","volume":"52","author":"Mace","year":"1978","journal-title":"Mutation Research"},{"key":"10.1016\/j.tiv.2011.05.002_b0155","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2165\/00003495-199855020-00012","article-title":"Fexofenadine","volume":"55","author":"Markham","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/j.tiv.2011.05.002_b0160","series-title":"Physicians\u2019 Desk Reference (PDR)","year":"2005"},{"key":"10.1016\/j.tiv.2011.05.002_b0165","series-title":"Veterinary Drug Handbook","author":"Plumb","year":"1999"},{"issue":"4","key":"10.1016\/j.tiv.2011.05.002_b0170","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/09723757.2004.11885904","article-title":"Chromosome damage induced by ferric chloride in human peripheral lymphocytes","volume":"4","author":"Poddar","year":"2004","journal-title":"International Journal of Human Genetics"},{"key":"10.1016\/j.tiv.2011.05.002_b0175","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1046\/j.1365-2222.1999.0290s3212.x","article-title":"Cardiovascular safety of fexofendaine HCl","volume":"3","author":"Pratt","year":"1999","journal-title":"Clinical and Experimental Allergy"},{"issue":"1","key":"10.1016\/j.tiv.2011.05.002_b0180","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2165\/00003495-199600521-00004","article-title":"A preclinical overview of ebastine","volume":"52","author":"Roberts","year":"1996","journal-title":"Drugs"},{"key":"10.1016\/j.tiv.2011.05.002_b0185","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/00001813-199312000-00005","article-title":"Mitotic index and cell proliferation kinetics for the identification of antineoplastic activity","volume":"4","author":"Rojas","year":"1993","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.tiv.2011.05.002_b0190","first-page":"390","article-title":"Induced micronucleus frequencies in peripheral lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families","volume":"60","author":"Rothfuss","year":"2000","journal-title":"Cancer Research"},{"issue":"2","key":"10.1016\/j.tiv.2011.05.002_b0195","first-page":"223","article-title":"The anticancer homeopathic composite \u201cCanova Method\u201d is not genotoxic for human lymphocytes in vitro","volume":"2","author":"Seligmann","year":"2003","journal-title":"Genetics and Molecular Research"},{"key":"10.1016\/j.tiv.2011.05.002_b0200","series-title":"Allergy Principles and Practice","first-page":"834","article-title":"Antihistamines","author":"Simons","year":"2003"},{"key":"10.1016\/j.tiv.2011.05.002_b0205","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S1081-1206(10)63061-X","article-title":"Peripheral H1-blockade effect of fexofenadine","volume":"79","author":"Simons","year":"1997","journal-title":"Annals of Allergy, Asthma and Immunology"},{"issue":"2","key":"10.1016\/j.tiv.2011.05.002_b0210","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2165\/00003495-200059020-00020","article-title":"Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathetic urticaria","volume":"59","author":"Simpson","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.tiv.2011.05.002_b0215","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1383-5742(98)00016-7","article-title":"A review and investigation into the mechanistic basis of the genotoxicity of antihistamines","volume":"411","author":"Snyder","year":"1998","journal-title":"Mutation Research"},{"key":"10.1016\/j.tiv.2011.05.002_b0220","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1383-5742(01)00055-2","article-title":"A review of the genotoxicity of marketed pharmaceuticals","volume":"488","author":"Snyder","year":"2001","journal-title":"Mutation Research"},{"issue":"1","key":"10.1016\/j.tiv.2011.05.002_b0225","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1383-5718(96)00140-4","article-title":"Genotoxicity of malathion in human lymphocytes assessed using the micronucleus assay in vitro and in vivo: a study of malathion-exposed workers","volume":"388","author":"Titenko-Holland","year":"1997","journal-title":"Mutation Research"},{"key":"10.1016\/j.tiv.2011.05.002_b0230","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0165-1110(93)90001-4","article-title":"Sister-chromatid exchange: second report the Gene-Tox Program","volume":"297","author":"Tucker","year":"1993","journal-title":"Mutation Research"},{"key":"10.1016\/j.tiv.2011.05.002_b0235","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF00373399","article-title":"Mutagenicity tests with astemizole in vitro and in vivo","volume":"50","author":"Vanparys","year":"1982","journal-title":"Archives of Toxicology"},{"key":"10.1016\/j.tiv.2011.05.002_b0240","first-page":"1154","article-title":"Terfenadine, the first non-sedating antihistamine","volume":"32","author":"Woodward","year":"1982","journal-title":"Arzneimittel-Forschung\/Drug Research"}],"container-title":["Toxicology in Vitro"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887233311001263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887233311001263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T17:24:30Z","timestamp":1560187470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887233311001263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0887233311001263"],"URL":"https:\/\/doi.org\/10.1016\/j.tiv.2011.05.002","relation":{},"ISSN":["0887-2333"],"issn-type":[{"value":"0887-2333","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}